Recent events
Recent events tied to this brand in public sources.
Back to profile15 entries
2021
BeiGene announces planned STAR Market initial public offering
BeiGene announced that it had launched a plan for an initial public offering on the Shanghai Stock Exchange STAR Market. It proposed issuing 115,055,260 ordinary shares; completion, size, and terms remained subject to market conditions and other factors.
2021
BeiGene completes land acquisition for planned U.S. manufacturing and clinical R&D site
BeiGene announced that it had completed the land acquisition in Hopewell, New Jersey, for a planned manufacturing base and clinical R&D center. Initial construction was planned to begin in 2022, with completion targeted for the end of 2023 or 2024.
2020
BeiGene announces inclusion in Stock Connect and the Hang Seng Composite Index
BeiGene announced that its Hong Kong-listed ordinary shares would enter the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect programs on September 7, 2020, and be included in the Hang Seng Composite Index.
2020
BeiGene and Danxu Bio enter antibody licensing agreement
BeiGene and Beijing Danxu Biopharmaceutical signed an exclusive license agreement under which BeiGene will develop, manufacture, and commercialize Danxu's investigational COVID-19 neutralizing antibodies outside Greater China.
2020
BeiGene appoints Corsee Sanders to its board
BeiGene announced the appointment of Corsee Sanders to its board of directors and her addition to the board audit and scientific advisory committees.
2020
Bio-Thera and BeiGene sign China agreement for BAT1706
Bio-Thera and BeiGene announced that they had signed an agreement covering the licensing, distribution and supply of Bio-Thera’s investigational biosimilar BAT1706 in China, including Hong Kong, Macao and Taiwan. The agreement was subject to approval at Bio-Thera’s September 2020 shareholders’ meeting.
2020
Assembly and BeiGene announce China licensing collaboration for three hepatitis B drug candidates
Assembly Biosciences and BeiGene announced a collaboration granting BeiGene exclusive rights to develop and commercialize three clinical-stage hepatitis B core inhibitor candidates in China, including Hong Kong, Macao, and Taiwan. Assembly is to receive a $40 million upfront payment and may receive milestone payments and royalties.
2020
BeiGene announces $2.08 billion equity financing
BeiGene announced a registered direct offering of 145,838,979 shares to existing investors, with gross proceeds of approximately $2.08 billion. The offering was expected to close around July 15, 2020.
2020
BeiGene announces pricing of approximately $2.08 billion registered direct offering
BeiGene announced the pricing of a registered direct offering of 145,838,979 ordinary shares to certain existing investors, with gross proceeds of approximately $2.08 billion. The offering was expected to close around July 15, subject to customary closing conditions.
2020
BeiGene reports first-quarter 2020 results
BeiGene released its first-quarter 2020 financial results, reporting revenue of $52.06 million, down 33.1% year over year.
2020
BeiGene expects temporary ABRAXANE supply interruption in China
BeiGene said it expected the regulatory suspension of Bristol Myers Squibb's albumin-bound paclitaxel product to cause a temporary interruption in China's supply of ABRAXANE. BeiGene said it was working with Bristol Myers Squibb on corrective work at the existing production site and an application to supply China from another factory.
2020
Amgen completes its equity investment in BeiGene
Amgen completed its purchase of approximately 20.5% of BeiGene's shares for about $2.8 billion.
2020
BeiGene and Amgen's global oncology partnership takes effect
BeiGene announced that its global oncology strategic partnership with Amgen, agreed on October 31, 2019, had received shareholder approval, met other closing conditions, and become effective.
2019
BeiGene and Shanghai East Hospital establish clinical research partnership
BeiGene and Shanghai East Hospital established a strategic partnership involving clinical research and other areas, including clinical trials, anti-tumor drug development, clinical application of new technologies, academic exchanges, and training research and management personnel.
2019
Amgen agrees to acquire a 20.5% stake in BeiGene
As part of the announced transaction, Amgen agreed to purchase 20.5% of BeiGene's shares for approximately $2.7 billion in cash or at $174.85 per American depositary share.